These studies have established SGLT-2 inhibitors and GLP-1 receptor agonists as the two medication classes for the treatment of type 2 diabetes, which do not only provide glycaemic control and body weight reductions without provoking hypoglycaemic episodes, but also show a potential for reducing the risk for a composite endpoint composed of cardiovascular events like acute myocardial infarction, stroke, cardiovascular death (major adverse cardiovascular events or MACE) in the majority of studies1–3,10,11,13,14,16. This evidence concerns the gene SLC5A2 and Stroke.